Compare · MO vs NAGE
MO vs NAGE
Side-by-side comparison of Altria Group Inc. (MO) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $123.29B, about 604.0x NAGE ($204.1M).
- Over the past year, MO is up 15.5% and NAGE is down 66.0% - MO leads by 81.5 points.
- NAGE has been more active in the news (6 items in the past 4 weeks vs 3 for MO).
- MO has more recent analyst coverage (21 ratings vs 1 for NAGE).
- Company
- Altria Group Inc.
- Niagen Bioscience Inc.
- Price
- $75.10+1.69%
- $2.49-3.49%
- Market cap
- $123.29B
- $204.1M
- 1M return
- +7.72%
- -16.86%
- 1Y return
- +15.49%
- -65.98%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 6
- Recent ratings
- 21
- 1
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- SEC Form 4 filed by Altria Group Inc.
- Altria to Host Webcast of 2026 Third-Quarter and Nine-Months Results
- SEC Form 8-K filed by Altria Group Inc.
- Director Mcquade Kathryn B. bought $101,430 worth of shares (1,500 units at $67.62), increasing direct ownership by 1% to 114,929 units (SEC Form 4)
- New insider Presley Steven W. claimed ownership of 1,081 shares (SEC Form 3)
- Altria Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Altria Announces Election of Steve Presley to Altria’s Board of Directors
- Altria Increases Quarterly Dividend to $1.11 Per Share
- Altria Announces Arrangement with Philip Morris International to Enhance Operational Efficiency
- Philip Morris International Announces Contract Manufacturing Collaboration with Altria
Latest NAGE
- Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
- Niagen Bioscience to Present at LD Micro 20th Annual Main Event
- Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
- Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
- Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
- Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
- Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
- Niagen Bioscience to Present at Longevity Investors Conference
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit